CRISPR in Huntington’s Disease Treatment
DOI:
https://doi.org/10.58445/rars.1948Keywords:
CRISPR, Huntington’s Disease, genetic disordersAbstract
Millions of people around the world suffer from genetic disorders, which diminish their quality of life and present significant challenges for them and their families. One such condition is Huntington’s Disease (HD), a genetic neurodegenerative disorder that progressively impacts one’s motor control, cognitive function, and mental health over time (Huntington’s Disease - NORD, 2015). Individuals diagnosed with HD experience a range of symptoms such as involuntary movements, emotional instability, and memory loss, all of which are life changing (Cleveland Clinic, 2017). Currently, available treatments are focused on symptom management and there is no cure. However, advancements in gene therapy, especially CRISPR-Cas9, offer a chance to address the root cause of Huntington’s Disease. This paper provides an overview of Huntington’s Disease and examines how CRISPR-Cas9 could lead to new treatment options for this condition.
References
Cleveland Clinic. (2017). Huntington’s Disease | Cleveland Clinic. Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/14369-huntingtons-disease
NORD. (2015). Huntington’s Disease - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders); NORD. https://rarediseases.org/rare-diseases/huntingtons-disease/
National Institute of Neurological Disorders and Stroke. (2022). Huntington’s Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease
Johnson, A., Paulsen, J., Lovecky, D., & Tarapata, K. (n.d.). Understanding Behavior In Huntington’s Disease: A Guide For Professionals. https://hdsa.org/wp-content/uploads/2015/03/Understanding-Behavior.pdf
Mayo Clinic. (2020, April 14). Huntington’s disease - Symptoms and causes. Mayo Clinic; Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117
Medline Plus. “Huntington’s Disease: MedlinePlus Genetics.” Medlineplus.gov, 2020, medlineplus.gov/genetics/condition/huntingtons-disease/.
Ferguson, M. W., Kennedy, C. J., Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022). Current and Possible Future Therapeutic Options for Huntington’s Disease. Journal of Central Nervous System Disease, 14(35615642), 117957352210925. https://doi.org/10.1177/11795735221092517
Redman, Melody, et al. “What Is CRISPR/Cas9?” Archives of Disease in Childhood - Education & Practice Edition, vol. 101, no. 4, 2016, pp. 213–215, www.ncbi.nlm.nih.gov/pmc/articles/PMC4975809/, https://doi.org/10.1136/archdischild-2016-310459.
Alkanli, S. S., Alkanli, N., Ay, A., & Albeniz, I. (2022). CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease. Molecular Neurobiology, 60(3). https://doi.org/10.1007/s12035-022-03150-5
Mengstie, M. A., Azezew, M. T., Dejenie, T. A., Teshome, A. A., Admasu, F. T., Teklemariam, A. B., Mulu, A. T., Agidew, M. M., Adugna, D. G., Geremew, H., & Abebe, E. C. (2024). Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. Biologics: Targets and Therapy, 18(1), 21–28. https://doi.org/10.2147/BTT.S429411
Schleidgen, S., Dederer, H.-G., Sgodda, S., Cravcisin, S., Lüneburg, L., Cantz, T., & Heinemann, T. (2020). Human germline editing in the era of CRISPR-Cas: risk and uncertainty, intergenerational responsibility, therapeutic legitimacy. BMC Medical Ethics, 21(1). https://doi.org/10.1186/s12910-020-00487-1
Mühlau, M., Winkelmann, J., Rujescu, D., Giegling, I., Koutsouleris, N., Gaser, C., Arsic, M., Weindl, A., Reiser, M., & Meisenzahl, E. M. (2012). Variation within the Huntington’s Disease Gene Influences Normal Brain Structure. PLoS ONE, 7(1), e29809. https://doi.org/10.1371/journal.pone.0029809
Sioson, V. A., Kim, M., & Joo, J. (2021). Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomedical Engineering Letters, 11(3), 217–233. https://doi.org/10.1007/s13534-021-00199-4
Downloads
Posted
Categories
License
Copyright (c) 2024 Shrinidhi Sridhar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.